Get Full Coverage of ACC.14
From trial summaries to presentation slides, videos and news articles, get all of the hot clinical news from ACC.14 on CardioSource.org here. Also, read more in depth pieces about sessions throughout the meeting here and get perspectives from leaders on the ACC in Touch Blog. You can find wrap up videos from each day of the annual scientific sessions and hot trial videos on YouTube.
Coverage of the most significant trials from ACC.14 (click to access):
- CoreValve US Pivotal Trial: TAVR with a Self-Expanding Prosthesis Shows Lower Mortality Than Surgery
- SYMPLICITY HTN-3: Renal Artery Denervation Fails for Resistant HTN
- STABILITY: Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy
- AleCardio: Aleglitazar to Reduce CV Events in Patients With ACS and Diabetes
- CHOICE: Self-Expandable vs. Balloon Expandable Prostheses in Transfemoral TAVR Patients
- POISE-2 Trials: Evaluation of Low-Dose Clonidine and Aspirin in Patients at Risk For ASCVD
Convocation Recognizes Past, Present and Future ACC Leaders
ACC’s 63rd Annual Convocation recognizes ACC leaders, welcomed new Fellows and Associates and acknowledged the traditions and legacy of the institution of the American College of Cardiology. Read speeches from Convocation in their entirety from Immediate Past President John Gordon Harold, MD, MACC and newly minted ACC President Patrick T. O’Gara, MD, FACC here. Also, read O’Gara’s first JACC President’s Page and learn more about O’Gara mission in this Q&A.
FITs on the Go Videos
Check out the ACC.14 videos from FITs on the GO, the roving reporters who also happen to be ACC Fellows-in-Training. All of the videos are archived here. These ones in particular may be of interest:
- FITs on the GO correspondent Mike Cullen, MD talks with Immediate Past Board of Governors Chair David May, MD, PhD, FACC, about how Chapters are a “great entry point” to connecting with the ACC and getting involved.
- FITs on the GO get perspectives from physicians who are also members of Congress. In a second video, they get to hear from those in public office about their thoughts on the changes coming in health care. Representatives from Indiana, Louisiana, Georgia and California weigh in.
- Scott Wright, MD, FACC, discusses the temporary Sustainable Growth Rate fix with FITs on the GO, and gives insight into what it really means.
- FITs on the GO talk with ACC President Patrick T. O’Gara, MD, FACC, about research development awards and the ACC’s focus on improving patient care, as well as other topics of interest to the care team and FIT/early career members.
- Incoming Journal of the American College of Cardiology (JACC) Editor-in-Chief, Valentin Fuster, MD, PhD, MACC talks about new opportunities for FITs in JACC that will give contributors a global voice, and other bits of wisdom for those early in their cardiology career.
MOC Deadline Extended Through April 30
The American Board of Internal Medicine (ABIM) has extended the enrollment deadline for anyone choosing to participate in MOC through April 30. Those enrolled by this date will be reported as “Meeting MOC Requirements.” Otherwise, physician choosing not to enroll will be reported as “Certified, Not Meeting MOC Requirements.” The original deadline was March 31. The ABIM’s MOC changes, which took effect as of Jan. 1, apply to all certified physicians – including those originally certified prior to 1990 (grandparents) – and require specific proactive steps on the part of physicians over the next two years. ACC.14 hosted several sessions dedicated to helping cardiologists understand and meet the new requirements, as well as featured an MOC Complex to help with questions. In addition, the College is using an ongoing three-pronged strategy to help members not only understand, but meet, the new requirements. In addition to communicating with and answering questions from members, the College is also gathering and providing feedback to ABIM on the concerns of the cardiovascular community. Learn more about the MOC changes and ACC resources at CardioSource.org/MOC. Also read an ACC.14 guest blog post from ABIM President and CEO Richard J. Baron, MD, here.
FDA Issues Clarification on Sildenafil Use in Children with PAH
The U.S. Food and Drug Administration (FDA) is clarifying its previous recommendation related to prescribing sildenafil (Revatio) for children with pulmonary arterial hypertension (PAH). Sildenafil is FDA-approved only to treat PAH in adults, not in children; however, the FDA says health care professionals must consider whether the benefits of treatment with the drug are likely to outweigh its potential risks for each patient. FDA revised the sildenafil drug label in August 2012, adding a warning stating that “use of [sildenafil], particularly chronic use, is not recommended in children.” This recommendation was based on an observation of increasing mortality with increasing sildenafil doses in a long-term clinical trial in pediatric patients with PAH. FDA also issued a Drug Safety Communication at that time. Learn more here.
Congress Passes 12-Month SGR Patch
Despite a last ditch effort by Senate Finance Committee Chairman Ron Wyden to permanently repeal and replace the Sustainable Growth Rate (SGR) formula, the Senate passed the Protecting Access to Medicare Act of 2014 (H.R. 4302) on March 31 in a vote of 64-35. The legislation, which delays for 12 months a 24 percent Medicare physician payment cut that was set to kick in April 1, is the 17th patch that Congress has enacted since 1997. Last week, the House passed the bill by voice vote. Get more details on the provisions included here.
↑ Back to top ↑
ACC/AHA/HRS Guideline for the Management of Patients With AFib
The ACC, American Heart Association (AHA) and the Heart Rhythm Society, in collaboration with the Society of Thoracic Surgery, have released a new 2014 Guideline for the Management of Patients With Atrial Fibrillation (AFib) that incorporates new and existing knowledge derived from published clinical trials, basic science, and comprehensive review articles, along with evolving treatment strategies and new drugs. The guideline, which supersedes the "2006 ACC/AHA/ESC Guideline for the Management of Patients With Atrial Fibrillation" and two subsequent focused updates from 2011, contains the most updated consensus of clinicians with broad expertise related to AFib and its treatment, including adult cardiology, electrophysiology, cardiothoracic surgery, and heart failure.
ACC/AHA/SCAI Health Policy Statement on Clinical Standards For Cardiac Cath Lab Structured Reporting
The ACC, AHA and Society for Cardiovascular Angiography and Interventions, in collaboration with 14 other professional societies, on March 28 released a health policy statement in the Journal of the American College of Cardiology that defines the clinical standards for structured reporting in the cardiac catheterization suite. The goal of the statement is to provide a standardized means for how to report a variety of cardiac catheterization procedures and improve patient care by making clinical data more timely, accessible, consistent and usable. Learn more here.
ACC/AHA Statement on Cost/Value Methodology in Guidelines and Performance Measures
The ACC and the AHA will begin to include value assessments when developing guidelines and performance measures, in recognition of accelerating health care costs and the need for care to be of value to patients. The ACC/AHA Statement on Cost/Value Methodology in Guidelines and Performance Measures released March 27, states a key goal of achieving the best possible health outcomes with finite health care resources. Historically, value consideration and resource utilization were explicitly excluded from practice guidelines and performance measures formulations, though they were often implicitly considered. Learn more here.
↑ Back to top ↑